Cargando…

SIRPα blockade improves the antitumor immunity of radiotherapy in colorectal cancer

High-dose hypofractionated radiotherapy (HRT) is an important anticancer treatment modality that activates antitumor host immune responses. However, HRT for oligometastases of colorectal cancer (CRC) has shown frustrating results in the clinic. As part of immune evasion, myeloid cells express signal...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ji, Kai, Zhang, Yuhan, Jiang, Shengpeng, Sun, Lin, Zhang, Baozhong, Hu, Dongzhi, Wang, Jun, Zhao, Lujun, Wang, Ping, Tao, Zhen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10250547/ https://www.ncbi.nlm.nih.gov/pubmed/37291116 http://dx.doi.org/10.1038/s41420-023-01472-4

Ejemplares similares

Concerted BAG3 and SIRPα blockade impairs pancreatic tumor growth
por: De Marco, Margot, et al.
Publicado: (2022)

Targeting SIRPα in cancer
por: Ho, Jenny M., et al.
Publicado: (2013)

CD39 inhibition and VISTA blockade may overcome radiotherapy resistance by targeting exhausted CD8+ T cells and immunosuppressive myeloid cells
por: Zhang, Yuhan, et al.
Publicado: (2023)

A SIRPα‐Fc fusion protein enhances the antitumor effect of oncolytic adenovirus against ovarian cancer
por: Huang, Yao, et al.
Publicado: (2020)

Delivery of CD47 blocker SIRPα-Fc by CAR-T cells enhances antitumor efficacy
por: Chen, Huanpeng, et al.
Publicado: (2022)

Intratumoral SIRPα-deficient macrophages activate tumor antigen-specific cytotoxic T cells under radiotherapy
por: Bian, Zhen, et al.
Publicado: (2021)

Liposome-Based Co-Immunotherapy with TLR Agonist and CD47-SIRPα Checkpoint Blockade for Efficient Treatment of Colon Cancer
por: Chang, Rui, et al.
Publicado: (2023)

Anticancer efficacy of monotherapy with antibodies to SIRPα/SIRPβ1 mediated by induction of antitumorigenic macrophages
por: Sakamoto, Mariko, et al.
Publicado: (2021)

The SIRPα–CD47 immune checkpoint in NK cells
por: Deuse, Tobias, et al.
Publicado: (2021)

Functional characterization of the selective pan-allele anti-SIRPα antibody ADU-1805 that blocks the SIRPα–CD47 innate immune checkpoint
por: Voets, Erik, et al.
Publicado: (2019)

Preclinical characterization of the novel anti-SIRPα antibody BR105 that targets the myeloid immune checkpoint
por: Wu, Zhen-Hua, et al.
Publicado: (2022)

Synapse Maturation by Activity-Dependent Ectodomain Shedding of SIRPα
por: Toth, Anna B., et al.
Publicado: (2013)

CD47/SIRPα axis: bridging innate and adaptive immunity
por: van Duijn, Anneloes, et al.
Publicado: (2022)

Cancer Therapy Targeting CD47/SIRPα
por: Dizman, Nazli, et al.
Publicado: (2021)

Macrophage checkpoint blockade: results from initial clinical trials, binding analyses, and CD47-SIRPα structure–function
por: Jalil, AbdelAziz R, et al.
Publicado: (2020)

Targeting CD47-SIRPα axis for Hodgkin and non-Hodgkin lymphoma immunotherapy
por: Zhao, Pengcheng, et al.
Publicado: (2023)

Loss of microglial SIRPα promotes synaptic pruning in preclinical models of neurodegeneration
por: Ding, Xin, et al.
Publicado: (2021)

Insights into CD47/SIRPα axis-targeting tumor immunotherapy
por: Zhang, Xuyao, et al.
Publicado: (2018)

Nomograms for predicting progression and efficacy of post-operation radiotherapy in IIIA-pN2 non-small cell lung cancer patients
por: Zhang, Baozhong, et al.
Publicado: (2017)

Glioblastoma Immunotherapy Targeting the Innate Immune Checkpoint CD47-SIRPα Axis
por: Hu, Jinyang, et al.
Publicado: (2020)

OX130 Monoclonal Antibody Recognizes Human SIRPβ1 but Cross-Reacts on SIRPα from One Allele
por: Hatherley, Deborah, et al.
Publicado: (2016)

SIRPα-αCD123 fusion antibodies targeting CD123 in conjunction with CD47 blockade enhance the clearance of AML-initiating cells
por: Tahk, Siret, et al.
Publicado: (2021)

CD47/SIRPα pathway mediates cancer immune escape and immunotherapy
por: Jia, Xiao, et al.
Publicado: (2021)

Sodium stibogluconate and CD47-SIRPα blockade overcome resistance of anti-CD20–opsonized B cells to neutrophil killing
por: van Rees, Dieke J., et al.
Publicado: (2022)

CD47–SIRPα-targeted therapeutics: status and prospects
por: Maute, R., et al.
Publicado: (2022)

Leishmania Infection-Induced Proteolytic Processing of SIRPα in Macrophages
por: Hirai, Hana, et al.
Publicado: (2023)

Membrane-Mediated Cooperative Interactions of CD47 and SIRPα
por: Li, Long, et al.
Publicado: (2023)

The Ap-2α/Elk-1 axis regulates Sirpα-dependent tumor phagocytosis by tumor-associated macrophages in colorectal cancer
por: Wang, Xiaojiao, et al.
Publicado: (2020)

The influence of the metastasis pattern of mediastinal lymph nodes on the postoperative radiotherapy’s efficacy for the IIIA-pN2 non-small-cell lung cancer: a retrospective analysis of 220 patients
por: Zhang, Baozhong, et al.
Publicado: (2016)

PD-1 blockade attenuates immunosuppressive myeloid cells due to inhibition of CD47/SIRPα axis in HPV negative head and neck squamous cell carcinoma
por: Yu, Guang-Tao, et al.
Publicado: (2015)

Potential New Cancer Immunotherapy: Anti-CD47-SIRPα Antibodies
por: Lu, Quansheng, et al.
Publicado: (2020)

Advances in Anti-Tumor Treatments Targeting the CD47/SIRPα Axis
por: Zhang, Wenting, et al.
Publicado: (2020)

The TSP1-CD47-SIRPα interactome: an immune triangle for the checkpoint era
por: Montero, Enrique, et al.
Publicado: (2023)

SIRPα polymorphisms, but not the prion protein, control phagocytosis of apoptotic cells
por: Nuvolone, Mario, et al.
Publicado: (2013)

The Immunotherapeutic Effect of SIRPα-Silenced DCs against Cervical Cancer
por: Li, Xiaojie, et al.
Publicado: (2020)

Targeting of SIRPα as a potential therapy for Langerhans cell histiocytosis
por: Okamoto, Takeshi, et al.
Publicado: (2023)

Preliminary Results about Application of Intensity-Modulated Radiotherapy to Reduce Prophylactic Radiation Dose in Limited-Stage Small Cell Lung Cancer
por: Liu, Zhiyan, et al.
Publicado: (2018)

Nicotine Suppresses Phagocytic Ability of Macrophages by Regulating the miR-296-3p–SIRPα Axis
por: Liu, Zhen, et al.
Publicado: (2023)

Clinical results of intensity-modulated radiotherapy for 250 patients with cervical and upper thoracic esophageal carcinoma
por: Zhang, Jiaqi, et al.
Publicado: (2019)

BYON4228 is a pan-allelic antagonistic SIRPα antibody that potentiates destruction of antibody-opsonized tumor cells and lacks binding to SIRPγ on T cells
por: van Helden, Mary J, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_deq44s1kh1p4cvgak1f5sa48si